The explant was homogenized in 100 μL modified RIPA buffer (50 mM Tris-HCl (pH 7.4), 1% Triton X-100, 0.2% sodium dodecyl sulfate [SDS], 1 mM dithiothreitol, 2 mM EGTA, 4 mM EDTA, 2 mM sodium orthovanadate, and 100 mM NaCl) with fresh protease inhibitors, including 0.2 mM phenylmethylsulfonyl fluoride (PMSF) and 10 μg/mL each of aprotinin, pepstatin A, and soybean trypsin inhibitor (Sigma, St. Louis, MO). Samples were incubated at 4°C for 30 minutes to solubilize proteins, and insoluble materials were pelleted by centrifugation at 14,000g for 10 minutes. Protein concentration was determined with a protein assay (Bio-Rad, Richmond, CA), and equal total protein content was loaded into 7.5% SDS-polyacrylamide gels (SDS-PAGE; Bio-Rad). Proteins were transferred to polyvinylidene difluoride membranes (Millipore, Bedford, MA), blocked by 1% bovine serum albumin for 60 minutes, and incubated with the primary antibodies of anti-ZO-1, anti-occludin, anti-claudin-1, anti-E-cadherin, and anti-β-catenin, followed by horseradish peroxidase-conjugated secondary antibody. The membranes were then washed and developed with the addition of a chemiluminescence detection kit (Amersham Pharmacia Biotech, Piscataway, NJ).